Posted by Michael Wonder on 22 May 2024
Sirolimus for the treatment of patients with facial angiofibroma caused by tuberous sclerosis complex
22 May 2024 - NICE is unable to make a recommendation on the use of sirolimus (Hyftor) for the treatment of patients 6 years of age and over with facial angiofibroma caused by tuberous sclerosis complex because Plusultra Pharma did not provide an evidence submission.
NICE will review this decision if Plusultra Pharma decides to make a submission.
